Beta-blockers: Focus on mechanism of action which beta-blocker, when and why?

Acta Cardiologica

Volumn 65, Issue 5, 2010, Pages 565-570

  Gorre, Frauke ^a   Vandekerckhove, Hans ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b Algemeen Ziekenhuis Sint Lucas Gent   (Belgium)

Author keywords

Adrenoreceptor; Beta adrenoreceptor antagonist; Sympathetic nervous system

Indexed keywords

ACEBUTOLOL; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; CELIPROLOL; LABETALOL; METOPROLOL; NEBIVOLOL; PINDOLOL; PROPRANOLOL; SOTALOL;

ANTIHYPERTENSIVE ACTIVITY; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIASTOLIC HEART FAILURE; DRUG INDICATION; DRUG METABOLISM; GLUCOSE METABOLISM; HEART ARRHYTHMIA; HEART PROTECTION; HUMAN; HYPERTENSION; INTRINSIC SYMPATHOMIMETIC ACTIVITY; LIPID METABOLISM; PATHOPHYSIOLOGY; REVIEW; SURVIVAL; SYSTOLIC HEART FAILURE; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; HEART FAILURE; HEART RATE; HUMANS; RECEPTORS, ADRENERGIC, BETA; SYMPATHETIC NERVOUS SYSTEM; VASODILATOR AGENTS;

EID: 78149400043     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.65.5.2056244     Document Type: Review

References (33)

1. The task force members of the task force on beta-blockers of the European Society of Cardiology. Expert consensus document on B-adrenergic receptor blockers. Eur Heart J 2004; 25: 1341-62.
2. Cruickshank JM. Beta-blockers in clinical practice, Chapter 2-7. Churchill Livingstone, New York, 1988.
3. Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The Sympathetic nervous system in heart failure. J Am Coll Cardiol 2009; 54: 1747-62.
4. Man in 't Veld AJ, Schalekamp MA. Effects of 10 different beta-adrenoceptor antagonists on hemodynamics, plasma rennin activity and plasma norepinephrine in hypertension: the key role of vascular resistance changes in relation to partial agonist activity. J Cardiovasc Pharmacol 1983; 5 (Suppl 1): S30-45.
5. Bakris G. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade. J Cardiovasc Pharmacol 2009; 53: 379-87.
6. Van Bortel L. Do beta-blockers still have a place? Tijdschr Geneeskd 2007; 63(8): 342-6 [in Dutch].
7. Leonetti G, Sampieri L, Cuspidi C, Terzoli L, Rupoli L, Fruscio M, Gradnik R, Zanchetti A. Does beta 1-selective agonistic activity interfere with the antihypertensive efficacy of beta1-selective blocking agents? J Hypertension 1985; 3(3): S243-5. (Pubitemid 17199971)
8. Cruickshank JM. Are we misunderstanding beta-blockers. Int J Cardiol 2007; 120: 10-27.
9. Chrysant SG, Chrysant GS, Dimas B. Current and future status of beta-blockers in the treatment of hypertension. Clin Cardiol 2008; 31(6): 249-52.
10. Wiysonge CSU, Bradley HA, Mayosi BM, Maroney RT, Mbewu A, Opie L, Volmink J. Beta-blockers for hypertension. Cochrane Database of Systematic Reviews 2008, Issue 4.
11. The CAFÉ investigators for the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Investigators, CAFÉ steering committee and writing committee, Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation 2006; 113; 1213-25.
12. Williams B, Lacy PS. Impact of heart rate on central aortic pressures and hemodynamics. Analysis from the CAFÉ (Conduit Artery Function Evaluation) study: CAFÉ-Heart rate. J Am Coll Cardiol 2009; 54, 705-13.
13. Gilles TD. Antihypertensive therapy and cardiovascular risk. Are all antihypertensives equal? Hypertension 1992; 19 (S1): 124-9.
14. Franklin SS, Pio JR, Wong ND, Larson MG, Leip EP, Vasan RS, Levy D. Predictors of new-onset diastolic and systolic hypertension: the Framingham Heart Study. Circulation 2005; 111: 1121-7.
15. Williams BR, Kim J. Cardiovascular drug therapy in the elderly: theoretical and practical considerations. Drugs aging 2003; 20(6): 445-63. (Pubitemid 36637087)
16. Bangalore S, Parkar S, Grossman E, Messerli FH. A meta-analysis of 94,492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007; 100: 1254-62.
17. Pepine CJ, Cooper-DeHoff RM. Cardiovascular therapies and risk for development of diabetes. J Am Coll Cardiol 2004; 44: 509-12.
18. Verdecchia P, Angeli F, Reboldi G. New-onset diabetes, antihypertensive treatment and outcome. Hypertension 2007; 50: 459-60.
19. Musini VM, Wright JM, Basset K, Jauca CD. Blood pressure lowering efficacy of loop diuretics for primary hypertension. Cochrane Database of Systematic Reviews 2009, Issue 4.
20. Cooper-DeHoff RM, Pacanowski MA, Pepine CJ. Cardiovascular therapies and associated glucose homeostasis. J Am Coll Card 2009; 53: S28-34.
21. Hall SA, Cigarrroa CG, Marcoux L, Risser RC, Grayburn PA, Eichhorn EJ. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade. J Am Coll Cardiol 1995; 25: 1154-61.
22. MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 2000; 283: 1295-1302.
23. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
24. COPERNICUS Study Group. Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002; 106: 2194-9. (Pubitemid 35222212)
25. Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, Böhm M, Anker SD, Thompson SG, Poole-Wilson PA; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215-25.
26. Borbély A, Papp Z, Edes I, Paulus WJ. Molecular determinants of heart failure with normal left ventricular ejection fraction. Pharmacol Rep 2009; 61: 139-45.
27. Koprowki A, Gruchala M, Rynkiewicz A. Management of left ventricular diastolic heart failure: is it only blood pressure control? Curr Opin Cardiol 2009; 24: 161-6.
28. Willenheimer R, van Veldhuisen DJ, Silke B, Erdmann E, Follath F, Krum H, Ponikowski P, Skene A, van de Ven L, Verkenne P, Lechat P; CIBIS III Investigators. Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III. Circulation 2005; 12: 2426-35.
29. Palatini P. Elevated heart rate in cardiovascular diseases: a target for treatment? Progr Cardiovasc Dis 2009; 52: 46-60.
30. Fox K, Borer JS, Camm AJ, Danchin N, Ferrari R, Sendon JLL, Steg PG, Tardif JC, Tavazzi L, Tendera M, for the Heart Rate Working Group. Resting heart rate in cardiovascular disease. J Am Coll Cardiol 2007; 50: 823-30.
31. Galderisi M, D'Errico A. Beta blockers and coronary flow reserve. The importance of a vasodilatory action. Drugs 2008; 68: 579-90.
32. Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology, Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, Fox KA, Hasdai D, Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598-660.
33. Poldermans D, Bax JJ, Boersma E, De Hert S, Eeckhout E, Fowkes G, Gorenek B, Hennerici MG, Iung B, Kelm M, Kjeldsen KP, Kristensen SD, Lopez-Sendon J, Pelosi P, Philippe F, Pierard L, Ponikowski P, Schmid JP, Sellevold OF, Sicari R, Van den Berghe G, Vermassen F, Hoeks SE, Vanhorebeek I, Vahanian A, Auricchio A, Bax JJ, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, McGregor K, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, De Caterina R, Agewall S, Al Attar N, Andreotti F, Anker SD, Baron-Esquivias G, Berkenboom G, Chapouotot L, Cifkova R, Faggiano P, Gibbs S, Hansen HS, Iserin L, Israel CW, Kornowski R, Eizagaechevarria NM, Pepi M, Piepoli M, Priebe HJ, Scherer M, Stepinska J, Taggart D, Tubaro M; Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery, European Society of Cardiology; European Society of Anaesthesiology. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur Heart J 2009; 30: 2769-812.